Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet's Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB)

NCT00167583 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT00167583
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00167583 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet's Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB)
Lead sponsor
University Hospital Tuebingen
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2004
Completion date
December 31, 2014
Enrollment
37 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

behcet's disease, panuveitis, posterior uveitis, retinal vasculitis